EP0732938A4 - Procede pour traiter des troubles intestinaux - Google Patents

Procede pour traiter des troubles intestinaux

Info

Publication number
EP0732938A4
EP0732938A4 EP95902712A EP95902712A EP0732938A4 EP 0732938 A4 EP0732938 A4 EP 0732938A4 EP 95902712 A EP95902712 A EP 95902712A EP 95902712 A EP95902712 A EP 95902712A EP 0732938 A4 EP0732938 A4 EP 0732938A4
Authority
EP
European Patent Office
Prior art keywords
intestinal disorders
treating intestinal
treating
disorders
intestinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95902712A
Other languages
German (de)
English (en)
Other versions
EP0732938A1 (fr
Inventor
Graham Douglas Fischer Jackson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unisearch Ltd
Original Assignee
Unisearch Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPM8325A external-priority patent/AUPM832594A0/en
Application filed by Unisearch Ltd filed Critical Unisearch Ltd
Publication of EP0732938A1 publication Critical patent/EP0732938A1/fr
Publication of EP0732938A4 publication Critical patent/EP0732938A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP95902712A 1993-12-01 1994-12-01 Procede pour traiter des troubles intestinaux Withdrawn EP0732938A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPM2740/93 1993-12-01
AUPM274093 1993-12-01
AUPM8325/94 1994-09-21
AUPM8325A AUPM832594A0 (en) 1994-09-21 1994-09-21 Bile tnf
PCT/AU1994/000745 WO1995015179A1 (fr) 1993-12-01 1994-12-01 Procede pour traiter des troubles intestinaux

Publications (2)

Publication Number Publication Date
EP0732938A1 EP0732938A1 (fr) 1996-09-25
EP0732938A4 true EP0732938A4 (fr) 1997-03-19

Family

ID=25644589

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95902712A Withdrawn EP0732938A4 (fr) 1993-12-01 1994-12-01 Procede pour traiter des troubles intestinaux

Country Status (4)

Country Link
EP (1) EP0732938A4 (fr)
JP (1) JPH09505812A (fr)
CA (1) CA2177570A1 (fr)
WO (1) WO1995015179A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2121907T3 (es) * 1992-08-28 1998-12-16 Bayer Ag Uso de anticuerpos monoclonales anti-tnf para el tratamiento de meningitis bacterianas.
ES2220915T3 (es) 1993-09-24 2004-12-16 Advanced Immuni T, Inc. Peptidos lineales y ciclicos para el tratamiento o prevencion de la enfermedad de crohn y/o colitis ulcerosa.
DE69914932T2 (de) * 1998-10-20 2004-12-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
WO2011158904A1 (fr) 2010-06-18 2011-12-22 株式会社林原生物化学研究所 Agent thérapeutique pour des maladies inflammatoires contenant de l'adénosine n1-oxyde en tant que principe actif

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014455A1 (fr) * 1991-02-14 1992-09-03 The Rockefeller University PROCEDE POUR LIMITER LES CONCENTRATIONS ANORMALES DE TNF-α DANS LES TISSUS CHEZ L'HOMME
EP0526905A2 (fr) * 1991-08-07 1993-02-10 Yeda Research And Development Co. Ltd. Multimères des formes solubles des récepteurs TNF, leurs préparation et compositions pharmaceutiques les contenant

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8805792D0 (en) * 1988-03-11 1988-04-13 Celltech Ltd Medicaments
WO1990001950A1 (fr) * 1988-08-19 1990-03-08 Celltech Limited Produits pharmaceutiques pour therapie anti-neoplastique
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014455A1 (fr) * 1991-02-14 1992-09-03 The Rockefeller University PROCEDE POUR LIMITER LES CONCENTRATIONS ANORMALES DE TNF-α DANS LES TISSUS CHEZ L'HOMME
EP0526905A2 (fr) * 1991-08-07 1993-02-10 Yeda Research And Development Co. Ltd. Multimères des formes solubles des récepteurs TNF, leurs préparation et compositions pharmaceutiques les contenant

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KIMBERLEY J. VAN ZEE ET AL.,: "Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo", PROC. NATL. ACAD. SCI. USA, vol. 89, - June 1992 (1992-06-01), pages 4845 - 4849, XP002022372 *
MOHLER K. M. ET AL.,: "Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carrier and TNF antagonists", J. IMMUNOL., vol. 151, no. 3, 1 August 1993 (1993-08-01), pages 1548 - 1561, XP002022440 *
See also references of WO9515179A1 *

Also Published As

Publication number Publication date
EP0732938A1 (fr) 1996-09-25
JPH09505812A (ja) 1997-06-10
WO1995015179A1 (fr) 1995-06-08
CA2177570A1 (fr) 1995-06-08

Similar Documents

Publication Publication Date Title
EP0963787A4 (fr) Procede et dispositif pour produire des emulsions
EP0723469A4 (fr) Electrode curviligne et procede pour former des lesions
EP0831924A4 (fr) Procede de traitement de l'asthme
FR2723835B1 (fr) Procede pour creer des affichages de mode m anatomique
MA23212A1 (fr) Procede
FR2689517B1 (fr) Procede d'hydrogenation selective des hydrocarbures.
EP0738424A4 (fr) Procede et structure de passivation pour circuit integre
FR2701707B1 (fr) Procede pour la purification de lactide.
FI951702L (fi) Farmaseuttinen menetelmä osteoporoosin hoitamiseksi
EP0691674A3 (fr) Méthode pour produire des micro-dessins
EP0745315A4 (fr) Procede de soudage
FR2735445B1 (fr) Procede d'atterrissage pour des aeronefs non habites
FR2701880B1 (fr) Appareil et procede pour un soudage en intervalle etroit.
FR2657358B1 (fr) Procede et installation pour trempe par induction.
MA23790A1 (fr) Procede pour desactiver ou detruire des microorganismes
FR2729653B1 (fr) Procede de dephosphatation ameliore des eaux residuaires
FR2770534B1 (fr) Procede pour enlever des graffitis
MA24321A1 (fr) Procede pour un traitement nouveau
FR2740008B1 (fr) Procede pour la production de pates alimentaires et dispositif correspondant
EP0674026A3 (fr) Appareillage pour traitement électrolytique.
FR2692461B1 (fr) Appareil de cuisson et procede pour sa mise en óoeuvre.
EP0732938A4 (fr) Procede pour traiter des troubles intestinaux
FR2733228B1 (fr) Procede d'hydroxycarbonylation du butadiene
MA22848A1 (fr) Procede enzymatique pour la preparation des aryl-piperidines
MA22278A1 (fr) Procede pour le traitement de troubles respiratoires

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960614

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19970131

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19970312